With advances in the treatment of tumors with immune checkpoint blockers such as CTLA-4 and PD-1/PDL1, more therapeutic targets have been sought, including but not limited to the immune targets in the adenosine energy axis mentioned above, to overcome the problems of incomplete tumor regression or recurrence after treatment (3). The gene discussed is PDCD1; the disease is neoplasm.